Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine
详细信息 查看全文
- 作者：Xiancheng Zhang (1)
Peng He (1)
Zhongyu Hu (1)
Xingtai Wang (2)
Zhenglun Liang (1) - 刊名：Virology Journal
- 出版年：2011
- 出版时间：December 2011
- 年：2011
- 卷：8
- 期：1
- 全文大小：435KB
- 参考文献：1. Rehermann B, Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection. / Nat Rev Immunnol 2005,5(3):215-29. CrossRef
2. Bond WW, Petersen NJ, Favero MS: Viral hepatitis B: aspects of environmental control. / Health Lab Sci 1977,14(4):235-52.
3. Alter MJ, Margolis HS: The emergence of hepatitis B as a sexually transmitted disease. / Med Clin North Am 1990,74(6):1529-541.
4. World Health Organization: Programmes and projects - Immunization service delivery and accelerated disease control - New vaccines and technologies - Hepatitis B. [http://www.who.int/immunization_delivery/new_vaccines/hepb/en/index.html] 2008.
5. Liang XF, Bi S, Yang W, Wang L, Cui G, Zhang Y, Liu Y, Gong X, Chen Y, Wang Y, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y: Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. / Vaccine 2009,27(47):6550-557. CrossRef
6. Hem SL, Hogenesch H: Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. / Expert Rev Vaccines 2007,6(5):685-98. CrossRef
7. Morefield GL, Sokolovska A, Jiang D, HogenEsch H, Robinson JP, Hem SL: Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. / Vaccine 2005,23(13):1588-595. CrossRef
8. Kool M, Soullié T, van Nimwegen M, Willart MA, Muskens F, Jung S, Hoogsteden HC, Hammad H, Lambrecht BN: Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. / J Exp Med 2008,205(4):869-82. CrossRef
9. Lee WM: Hepatitis B virus infection. / N Engl J Med 1997,337(24):1733-745. CrossRef
10. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale RG, Koretzky GA, Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. / Nature 1995,374(6522):546-49. CrossRef
11. Mauri JM, Vallès M: Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients. / Collaborative Group of Girona. Nephrol Dial Transplant 1997,12(4):729-32. CrossRef
12. Singh AE, Plitt SS, Osiowy C, Surynicz K, Kouadjo E, Preiksaitis J, Lee B: Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants. / J Viral Hepat 2010, in press.
13. Park SD, Markowitz J, Pettei M, Weinstein T, Sison CP, Swiss SR, Levine J: Failure to respond to hepatitis B vaccine in children with celiac disease. / J Pediatr Gastroenterol Nutr 2007,44(4):431-35. CrossRef
14. Oyewumi MO, Kumar A, Cui Z: Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. / Expert Rev Vaccines 2010,9(9):1095-107. CrossRef
15. Saenz R, Souza CD, Huang CT, Larsson M, Esener S, Messmer D: HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen. / Vaccine 2011,28(47):7556-562. CrossRef
16. Pakravan N, Hashemi SM, Hassan ZM: Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent. / Cell Stress Chaperones 2011,16(1):41-8. CrossRef
17. Mastelic B, Ahmed S, Egan WM, Del Giudice G, Golding H, Gust I, Neels P, Reed SG, Sheets RL, Siegrist CA, Lambert PH: Mode of action of adjuvants: implications for vaccine safety and design. / Biologicals 2010,38(5):594-01. CrossRef
18. Dzierzbicka K, Ko?odziejczyk AM: Adjuvants--essential components of new generation vaccines. / Postepy Biochem 2006,52(2):204-11.
19. Schirmbeck R, Melber K, Kuhr?ber A, Janowicz ZA, Reimann J: Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo. / J Immunol 1994,1529(3):1110-119.
20. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM: CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. / J Immunol 1998,160(2):870-76.
21. Rossol S, Marinos G, Carucci P, V Singer M, Williams R, Naoumov NV: Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. / J Clin Invest 1997,99(12):3025-033. CrossRef
22. Salomon B, Bluestone JA: Complexities of Cd28/B 7 : ctla-4 co-stimulatory pathways in autoimmunity and transplantation. / Annu Rev Immunol 2001, 19:225. CrossRef
23. Chambers CA: The expanding world of co-stimulation: the two-signal model revisited. / Trends Immunol 2001,22(4):217-23. CrossRef
24. Alvarez E, Moqa E, Barquinero J, Sierra J, Briones J: Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response. / Gene Ther 2010,17(4):469-77. CrossRef
25. Holmstr?m K, Pedersen AW, Claesson MH, Zocca MB, Jensen SS: Identification of a microRNA signature in dendritic cell vaccines for cancer immunotherapy. / Hum Immunol 2010,71(1):67-3. CrossRef
26. Yong M, Mitchell D, Caudron A, Toth I, Olive C: Expression of maturation markers on murine dendritic cells in response to group A streptococcal lipopeptide vaccines. / Vaccine 2009,27(25-6):3313-318. CrossRef
27. Kakumu S, Ito S, Ishikawa T, Mita Y, Tagaya T, Fukuzawa Y, Yoshioka K: Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. / J Gastroenterol Hepatol 2000,15(4):431-36. CrossRef
28. Op den Brouw ML, Binda RS, van Roosmalen MH, Protzer U, Janssen HL, van der Molen RG, Woltman AM: Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. / Immunology 2009,126(2):280-89. CrossRef - 作者单位：Xiancheng Zhang (1)
Peng He (1)
Zhongyu Hu (1)
Xingtai Wang (2)
Zhenglun Liang (1)
1. The Second Division of Viral Vaccines, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, PR China
2. Massachusetts Department of Public Health, William A. Hinton State Laboratory Institute, Boston, the USA - ISSN：1743-422X
文摘
Background Hepatitis B vaccine adjuvant, alum, is generally used for vaccination although it does not stimulate Th1 immunity and 10% of the population has low or no antibody response. Efforts have been continued to find more efficient vaccine adjuvants for better antibody response as well as stimulation of Th1 immunity. Methods CpG DNA was used as an adjuvant for recombinant HBsAg to immunize 6- to 8-week-old female BALB/c mice with or without alum for different dosages. The production of HBsAb, CD80 and CD86 from dendritic cells, and cytokines IL-10, IL12, etc., were analyzed and compared for the performance of immunization. Results 5-20 μg CpG DNA had the best co-stimulation effect of HBsAb serum conversion for mice vaccinated with recombinant expressed HBsAg. The mice vaccinated with recombinant 20 μg CpG DNA and regular vaccine (containing alum adjuvant) had the highest concentration of antibody production. IL-12b, IL-12a and IL10 mRNA reached to the peak level between 3 and 6 hours after the CpG DNA induction in splenocytes. The expression levels of CD80 and CD86 leucocyte surface molecules were increased with 20 μg CpG DNA alone or with 20 μg CpG DNA and 4 μg HBsAg. Conclusions Our results confirmed the adjuvant effect of CpG DNA for HBsAg in the mouse model. The increase of IL10 and IL12 production suggested the involvement of Th1 cell activation. The activation of CD80 and CD86 molecules by CpG-ODN might be part of the mechanism of T/B cells coordination and the enhancement of recombinant HBsAg induced immune response.